Glenmark Pharmaceuticals quarterly results and financials

Glenmark Pharmaceuticals (GLENMARK)₹2,671+2.94%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Jun 2026 quarter (consolidated), Glenmark Pharmaceuticals reported sales of ₹4,023 Cr, up 23.2% from Jun 2025, and net profit of ₹483 Cr, up 927.6% year on year. For the year to Mar 2026, sales were ₹16,989 Cr and net profit ₹1,362 Cr.

Sales (Jun 2026): ₹4,023 Cr
Net profit (Jun 2026): ₹483 Cr
Sales (FY Mar 2026): ₹16,989 Cr
Net profit (FY Mar 2026): ₹1,362 Cr
EPS (Jun 2026): ₹17.07
Borrowings (Mar 2026): ₹594 Cr

Company filings, consolidated accounts; latest reported quarter Jun 2026

Glenmark Pharmaceuticals quarterly results

₹ crore unless stated; each column is a quarter.

Glenmark Pharmaceuticals Quarterly results
	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	3,209	2,510	3,067	3,248	3,437	3,390	3,259	3,266	6,053	3,903	3,772	4,023
Expenses	2,742	2,715	2,558	2,654	2,832	2,784	2,692	2,681	3,686	3,030	3,005	3,215
Operating Profit	464	−210	506	590	604	602	563	583	2,369	872	766	807
OPM %	14.1%	−8.0%	16.1%	18.0%	18.1%	18.1%	17.0%	18.1%	39.1%	22.1%	20.1%	20.1%
Other Income	−205	87.08	352	31.02	39.05	31.05	−361	−297	−1,185	−140	−184	66.07
Interest	121	134	149	39.98	48.01	51.95	66.94	57.94	65.97	40.94	42.98	53.92
Depreciation	141	147	151	118	120	123	125	130	141	154	148	173
Profit before tax	−6.01	−403	555	462	473	456	8.01	96.04	966	534	388	643
Tax %	996.9%	−18.0%	319.0%	26.0%	25.0%	23.9%	44.9%	50.9%	37.0%	23.9%	21.9%	24.9%
Exceptional items	−151	41.90	1,064	0.00	0.00	0.00	−365	−214	−924	−137	−261	0.00
Net Profit	−61.94	−331	−1,213	340	354	348	3.99	46.97	610	403	301	483
EPS (Rs)	−2.89	−12.41	−43.05	12.04	12.52	12.29	0.15	1.65	21.58	14.26	10.66	17.07

Glenmark Pharmaceuticals profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Glenmark Pharmaceuticals Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	7,573	9,083	9,089	9,880	10,643	10,959	12,308	11,602	11,830	13,335	16,989	17,752
Expenses	6,119	7,039	7,457	8,274	8,933	8,850	9,979	9,941	10,614	10,958	12,396	12,934
Operating Profit	1,442	2,045	1,623	1,591	1,704	2,090	2,334	1,642	1,199	2,358	4,590	4,814
OPM %	19.1%	22.1%	18.1%	16.1%	16.1%	19.0%	19.1%	14.0%	10.1%	18.0%	27.1%	27.1%
Other Income	20.01	−44.05	89.11	375	191	95.11	−101	−10.02	337	−259	−1,808	−1,443
Interest	179	237	286	335	377	353	298	349	515	207	209	204
Depreciation	234	264	302	326	417	444	487	569	582	486	573	616
Profit before tax	1,044	1,491	1,119	1,301	1,095	1,381	1,440	707	434	1,400	1,983	2,531
Tax %	29.0%	26.0%	27.9%	28.9%	29.0%	29.9%	30.9%	46.9%	430.0%	24.9%	30.9%	—
Exceptional items	0.00	−45.90	−0.99	106	19.95	28.94	−166	−311	2,964	−270	−1,588	−1,321
Net Profit	743	1,108	804	925	776	970	993	377	−1,433	1,047	1,362	1,796
EPS (Rs)	26.26	39.18	28.43	32.70	27.42	34.29	33.28	10.49	−53.07	37.00	48.16	63.57
Dividend payout %	8.0%	5.0%	7.0%	6.0%	9.0%	7.0%	7.0%	24.0%	−5.0%	7.0%	5.0%	—

Glenmark Pharmaceuticals balance sheet

₹ crore, at each year end.

Glenmark Pharmaceuticals Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	26.92	27.95	27.96	27.96	27.93	27.94	27.93	27.92	27.96	27.96	27.96	27.92
Reserves	1,753	3,596	4,459	5,126	5,569	6,028	7,027	9,036	9,428	7,811	8,806	10,466
Borrowings	3,799	3,991	4,723	4,642	4,453	4,869	4,986	3,963	4,608	1,232	2,474	594
Other Liabilities	2,738	2,583	2,560	2,806	3,237	3,737	3,526	4,022	5,314	5,288	4,691	8,812
Total Liabilities	8,317	10,200	11,770	12,603	13,287	14,662	15,568	17,051	19,378	14,359	15,999	19,899
Fixed Assets	2,007	2,585	2,745	3,018	3,655	5,009	5,109	5,865	5,398	4,194	4,470	6,368
CWIP	477	543	707	1,121	1,397	1,221	1,381	1,010	1,189	662	834	428
Investments	16.99	16.99	15.99	15.01	29.99	24.99	25.01	49.99	45.02	790	55.97	41.99
Other Assets	5,816	7,055	8,302	8,450	8,205	8,407	9,054	10,126	12,746	8,714	10,639	13,061
Inventories	1,273	1,573	2,144	2,035	2,257	2,142	2,285	2,508	2,381	2,520	3,038	3,439
Trade receivables	2,506	2,487	2,401	2,326	2,192	2,406	2,568	3,095	3,661	1,854	3,334	4,951
Cash & equivalents	775	857	1,057	1,234	938	1,110	1,138	1,410	1,160	1,657	1,704	1,175
Total Assets	8,317	10,200	11,770	12,603	13,287	14,662	15,568	17,051	19,378	14,359	15,999	19,899

Glenmark Pharmaceuticals cash flow

₹ crore, for each year.

Glenmark Pharmaceuticals Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	481	345	656	1,647	1,322	1,389	1,130	1,107	624	−265	−826	3,441
Cash from investing activity	−713	−950	−1,002	−1,004	−884	−775	−663	−316	−515	4,387	58.04	−1,283
Cash from financing activity	198	696	541	−466	−736	−443	−440	−518	−76.72	−3,892	784	−2,698
Net cash flow	−30.99	93.03	199	177	−297	174	27.99	272	32.01	215	17.01	−547
Capex	546	894	752	1,049	1,243	935	778	794	610	902	753	1,364
Free cash flow	−56.18	−546	−76.21	627	714	618	457	321	75.21	−1,165	−1,579	2,096
CFO / OP %	65.9%	56.9%	66.9%	123.9%	110.9%	109.0%	79.0%	71.9%	76.9%	64.9%	−6.0%	91.9%

Glenmark Pharmaceuticals ratios

Working-capital days and returns, by year.

Glenmark Pharmaceuticals Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	140	120	97	94	81	83	86	92	115	57	92	107
Inventory days	248	250	300	245	245	212	231	209	204	209	255	265
Days payable	380	309	244	226	242	211	227	191	173	211	217	289
Cash conversion cycle	7	60	151	112	84	83	89	109	146	55	128	82
Working capital days	47	51	125	99	64	54	67	65	141	−2	44	81
ROCE %	16.1%	19.0%	21.0%	15.1%	15.1%	14.0%	15.0%	16.0%	10.0%	12.0%	19.1%	40.1%

Glenmark Pharmaceuticals: frequently asked questions

What are the latest quarterly results of Glenmark Pharmaceuticals?

For the Jun 2026 quarter, Glenmark Pharmaceuticals reported sales of ₹4,023 Cr, up 23.2% year on year and net profit of ₹483 Cr, up 927.6% year on year. The operating margin was 20.1%.

What is the annual revenue of Glenmark Pharmaceuticals?

Glenmark Pharmaceuticals' sales for the year to Mar 2026 were ₹16,989 Cr; over the last twelve months they were ₹17,752 Cr.

What is the net profit of Glenmark Pharmaceuticals?

Net profit for the year to Mar 2026 was ₹1,362 Cr, and ₹1,796 Cr over the last twelve months. Earnings per share over the same trailing period were ₹63.57.

How much debt does Glenmark Pharmaceuticals have?

Glenmark Pharmaceuticals reported borrowings of ₹594 Cr at Mar 2026, against cash and equivalents of ₹1,175 Cr.

What is the free cash flow of Glenmark Pharmaceuticals?

Cash from operations was ₹3,441 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹2,096 Cr.

Loading…